CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer-Reference-Cited by-同舟云学术

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Published:2016-04 Issue:4 Volume:27 Page:654-660
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chiorean E.G.,Von Hoff D.D.,Reni M.,Arena F.P.,Infante J.R.,Bathini V.G.,Wood T.E.,Mainwaring P.N.,Muldoon R.T.,Clingan P.R.,Kunzmann V.,Ramanathan R.K.,Tabernero J.,Goldstein D.,McGovern D.,Lu B.,Ko A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/4/654/16700228/mdw006.pdf

Reference19 articles.

1. Cancer Facts and Figures 2014;American Cancer Society,2014

2. Current treatment options for pancreatic carcinoma;Castellanos;Curr Oncol Rep,2011

3. Specific antigen in serum of patients with colon carcinoma;Koprowski;Science,1981

4. Colorectal carcinoma antigens detected by hybridoma antibodies;Koprowski;Somatic Cell Genet,1979

5. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer;Boeck;Oncology,2006

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma;The Oncologist;2024-09-03

2. Pancreatic and Biliary Tract Cancers;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

3. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy;Cancer Medicine;2023-12-22

4. Therapy of Locally Advanced and Oligometastatic Pancreatic Adenocarcinoma;Cancers;2023-12-18

5. Increased plasma miR-370-3p expression in poor-outcome patients with pancreatic ductal adenocarcinoma;Pancreatology;2023-12